OHRP - OHR Pharmaceutical, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
+0.0600 (+2.27%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.6400
Bid2.2100 x 900
Ask2.7500 x 1000
Day's Range2.6000 - 2.7000
52 Week Range1.6000 - 6.6000
Avg. Volume186,558
Market Cap7.639M
Beta (3Y Monthly)0.86
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Benzinga4 months ago

    The Daily Biotech Pulse: Partial Clinical Hold On Advaxis Cervical Cancer Drug, Ohr's Reverse Split, Ironwood Starts Phase 1 Trial

    Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stocks hit 52-week highs Wednesday. Down In The Dumps (Biotech stocks hitting 52-week lows on Jan. 23) China ...

  • Here's more about what could be Pittsburgh's next public company
    American City Business Journals4 months ago

    Here's more about what could be Pittsburgh's next public company

    A move that stands to fast-forward a new entry into Pittsburgh’s public company ranks by mid-year has benefits for both parties. South Side startup NeuBase Therapeutics’ top executive said a reverse merger with a struggling, publicly traded pharmaceutical company will speed delivery of its treatments for genetic diseases. Dietrich Stephan, NeuBase CEO and founder, said during a joint press conference on Thursday that the merger between NeuBase and Ohr Pharmaceutical Inc. “accelerates getting our technologies into the clinic for those who desperately need them.” For Ohr, which announced the pending deal on Wednesday, it culminates a year-long evaluation of strategic alternatives that Jason Slakter, president and CEO, described as “exhausting.” But he believes the merger opens opportunities to create value for stockholders.

  • We're sorry this is all we were able to find about this topic.